Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

查看全文 作　　者：Enriqueta [1]Felip 机构地区：[1]不详 出　　处：《四川生理科学杂志》索引2021年第43卷第8期,共1页 摘　　要：Methods:IMpower010 was a randomised,multicentre,open-label,phase 3 study done at 227 sites in 22 countries and regions.Eligible patients were 18 years or older with completely resected stage IB(tumours>4 cm)to IIIA NSCLC per the Union Internationale Contre le Cancer and American Joint Committee on Cancer staging system(7th edition).Patients were randomly assigned(1:1)by a permuted-block method(block size of four)to receive adjuvant atezolizumab(1200 mg every 21 days;for 16 cycles or 1 year)or best supportive care(observation and regular scans for disease recurrence)after adjuvant platinum-based chemotherapy(one to four cycles).The primary endpoint,investigator-assessed disease-free survival,was tested hierarchically first in the stage II-IIIA population subgroup whose tumours expressed PD-L1 on 1%or more of tumour cells(SP263),then all patients in the stage II-IIIA population,and finally the intention-to-treat(ITT)population(stage IB-IIIA).Safety was evaluated in all patients who were randomly assigned and received atezolizumab or best supportive care.IMpower010 is registered with ClinicalTrials.gov,NCT02486718(active,not recruiting). 关 键 词：ADJUVANT chemotherapy CENTRE